Skip to main content

Table 5 Risk of chemotherapy resistance in breast cancer patients with different CYP2C9*2 genotypes and tumour characteristics

From: Association of cytochrome P450 genetic polymorphisms with neoadjuvant chemotherapy efficacy in breast cancer patients

Group

Allele/ Genotype CYP2C9*2 C430T

Positive neoadjuvant chemotherapy response

Negative neoadjuvant chemotherapy response

OR

CI (95%)

p

n

%

n

%

Cancer hereditary load

C

167

91.76

7

70.00

4.77

0.71 - 23.47

0.055

T

15

8.24

3

30.00

CC

76

83.52

2

40.00

0.13

0.01 - 1.29

0.04

CT

15

16.48

3

60.00

7.60

0.78 - 95.24

0.04

TT

0

0.00

0

0.00

*

  

Nodal form

C

371

91.83

10

71.43

4.50

0.97 - 16.60

0.027

T

33

8.17

4

28.57

CC

169

83.66

3

42.86

0.15

0.02 - 0.92

0.019

CT

33

16.34

4

57.14

6.83

1.09 - 48.12

0.019

TT

0

0.00

0

0.00

*

  

Cancer hereditary load + nodal form

C

136

91.89

3

50.00

11.33

1.32 - 91.23

0.01

T

12

8.11

3

50.00

CC

62

83.78

0

0.00

0.06

0.01 - 0.91

0.02

CT

12

16.22

3

100.00

15.50

1.08 - 826.12

0.02

TT

0

0.00

0

0.00

*

  
  1. *- OR, CI(95%) and p-values were not applicable to these samples.